$USPH

U.S. Physical Therapy’s (NYSE:USPH) Q1 CY2026 Earnings Results: Revenue In Line With Expectations

U.S. Physical Therapy (NYSE: USPH) reported Q1 CY2026 earnings with revenue of $198.3 million, meeting analyst expectations, but a GAAP loss of $0.12 per share, significantly missing estimates. The company's adjusted EBITDA also fell below projections, and its operating margin decreased year-over-year. Despite these challenges, the company highlighted new initiatives aimed at improving efficiency and care, expecting them to bear fruit in the latter half of the year.

Original reporting
Published May 7, 2026, 7:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 7, 2026, 8:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
U.S. Physical Therapy’s (NYSE:USPH) Q1 CY2026 Earnings Results: Revenue In Line With Expectations — source image
Decision brief

The 30-second read

$USPHNeutralMed
01

Why it matters

The earnings report suggests cautious trading; technical analysis indicates potential for short-term consolidation or minor decline.

02

Market read

The company's earnings provide insights into the healthcare services sector's current state, with limited broader market implications.

03

What to watch

Potential positive impact from upcoming healthcare policy changes or industry tailwinds that could offset short-term earnings concerns.

Timing: short-term (next 1-4 weeks)

Background

U.S. Physical Therapy reported Q1 CY2026 earnings with revenue meeting expectations but profits falling short, amid broader sector challenges.

Company-level read

Ticker impact

$USPHNeutralMedium confidence
Context

The company's Q1 CY2026 earnings report indicates mixed results with revenue meeting expectations but profitability falling short, which could influence short-term trading decisions.

Expected impact

Potential short-term sideways movement with slight downward bias due to earnings miss on profitability.

Evidence & confidence

Revenue met expectations, but profit decline and negative sentiment from earnings suggest limited upside in the immediate term.

Market effects

The healthcare services sector may experience cautious trading activity due to mixed earnings reports across similar companies.

Limited regional impact; effects are primarily company-specific.

Low; the news is primarily relevant to U.S.-based healthcare service providers.

Counterpoint

The company's initiatives to improve efficiency could lead to a turnaround in profitability in the coming quarters, presenting a buying opportunity for long-term investors.

Key entities

  • U.S. Physical Therapy

    A provider of outpatient physical therapy services in the U.S.

Related articles

$USPHMed

US Physical Therapy (USPH) Taps A Global Finance Veteran As CFO

US Physical Therapy (USPH) appointed Nchacha Etta as CFO, effective September 1. Etta previously held CFO roles at Omnicell (OMCL) and Johnson & Johnson Vision. USPH reported Q2 2026 revenue of $214.1M, up 8.5%, but net income fell to $9.9M from $12.4M. The company reaffirmed full-year adjusted EBITDA guidance of $102M-$106M.

$USPHMedAI 8/10

USPH (USPH) Q2 2026 Earnings Call Transcript

US Physical Therapy (USPH) discussed its Q2 2026 results and hospital-affiliation rollout. The company said Q2 revenue rose 8.5% to $214M, PT revenue rose 8.4% to $182M, and visits increased 6.6% to 1.662M. Net rate was $107.59. It cited $3.2M higher self-insured health care costs and expects clinic transitions to continue into Q3.

$USPHMed

U S PHYSICAL THERAPY INC /NV (USPH): Results of Operations and Financial Condition

U S PHYSICAL THERAPY INC /NV (USPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CONTACT: U.S. Physical Therapy, Inc. Jason Curtis, Interim Chief Financial Officer email: jcurtis@usph.com Chris Reading, Chief Executive Officer (713) 297-7000 Three Part Advisors Joe Noyons (817) 778-8424 USPH Reports Second Quarter 2026 Results, Reaffirms Full Yea

$SREHighAI 8/10

Sempra Locks In Petrobras for 20-Year U.S. LNG Supply Deal

Sempra Infrastructure signed a 20-year LNG supply deal with Petrobras for 800,000 tonnes per year, sourced from its Port Arthur LNG Phase 2 project in Texas. The agreement adds Petrobras as Sempra's first South American LNG customer. Port Arthur Phase 2, with a $14 billion estimated cost, is set to add 13 million tonnes per annum of liquefaction capacity and begin operations in 2030-2031. Sempra has previously secured LNG agreements with ConocoPhillips, JERA, and EQT for Phase 2.

$NVSLowAI 8/10

Back to Back Heart Drug Failures at Novartis and Novo Nordisk Undercut Two Leading Theories of Cardiovascular Risk

Novartis' pelacarsen and Novo Nordisk's ziltivekimab failed in Phase 3 trials, testing different cardiovascular risk theories. Both drugs did not reduce cardiovascular events despite lowering targets. Novartis reported pelacarsen's Lp(a)HORIZON trial results, while Novo Nordisk halted ziltivekimab's HERMES and ATHENA trials. Analysts estimated pelacarsen's peak sales at $4B-$6B. Both companies have other trials ongoing.